Salvo Health has raised $8.5 million in Series A funding to accelerate its hybrid, AI-enhanced care model designed to support gastrointestinal and metabolic care delivery through existing GI practices.
The round was led by ManchesterStory, City Light Capital, and Threshold Ventures, with participation from new and existing investors including The Artemis Fund, Torch Capital, Felicis Ventures, and others. The raise brings Salvo’s total equity funding to $21.6 million.
Salvo positions itself as an enablement layer for GI providers, offering a wraparound, continuous-care platform that integrates registered dietitians, behavioral health professionals, nurses, and AI-driven workflows—without replacing the physician or requiring practices to rebuild infrastructure. The model targets chronic GI and metabolic conditions including IBS, IBD, GERD, celiac disease, gastroparesis, MASLD, and obesity.